Malaria
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Only samples that meet the following criteria will be included in the current study: - The donor pregnant woman signed an informed consent authorizing the further use of their samples in studies of malaria and other infectious diseases. - Availability of subsequent samples from the same individual at Days 0, 28, 63;
Exclusion criteria
Exclusion criteria: - Absence of clinical data related to the samples; - Absence of placenta biopsy for analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic Accuracy: - Sensitivity and Specificity: Assess the sensitivity, specificity, and predictive value of IL-10, sTNF-RII, antibodies to DBL5, C5a, and VEGF in detecting PM using plasma samples. - Biomarker Performance Dataset: Compile data on biomarker performance to identify the most accurate candidates for inclusion in a future diagnostic platform. | — |
Secondary
| Measure | Time frame |
|---|---|
| Biomarker Variability: - Stage of Pregnancy: Analyze how biomarker levels vary across different stages of pregnancy to ensure they consistently detect PM. - Anti-malarial Treatments: Conduct a stratified analysis to observe biomarker variations across different anti-malarial treatments.;Integration with Intervention Strategies: - Enhance Effectiveness: Evaluate how the validated biomarkers can be incorporated with existing intervention strategies to improve their overall effectiveness in combating PM.;Conceptual Framework: - Diagnostic Tool Development: Create a prototype of a user-friendly, accurate, and feasible diagnostic tool suitable for resource-limited settings using the most promising biomarkers.;Temporal Dynamics: - Biomarker Levels: Track changes in biomarker levels at specific time points (days 0, 28, and 63) during pregnancy to understand their temporal dynamics in relation to PM. | — |
Countries
Burkina Faso
Contacts
Researcher